I en separat undersøgelse fik 224 patienter med genotype 2 eller 3 ViraferonPeg, 1, 5 mikrogram/ kg subkutant en gang ugentlig, i kombination med ribavirin 800 mg – 1. 400 mg p. o. i 6 måneder (baseret på kropsvægt, kun tre patienter, der vejede > 105 kg, fik 1. 400 mg dosen) (Tabel 7).
In a separate trial, 224 patients with genotype 2 or 3 received ViraferonPeg, 1.5 microgram/kg subcutaneously, once weekly, in combination with ribavirin 800 mg –1,400 mg p.o. for 6 months (based on body weight, only three patients weighing > 105 kg, received the 1,400 mg dose, which has not yet been validated) (Table 7).